Modulation of lipopolysaccharide-induced tumor necrosis factor-alpha and nitric oxide production by dopamine receptor agonists and antagonists in mice

G. Haskó, C. Szabé, K. Merkel, A. Bencsics, B. Zingarelli, E. Vízi

Research output: Contribution to journalArticle

Abstract

Dopamine and different dopaminergic drugs are widely used in the treatment of several immune-mediated diseases like Parkinson's disease or septic shock.Tumor necrosis factor-α and the free radical nitric oxide (NO) have been implicated in the pathogenesis of these pathophysiologic conditions. In the present study we have therefore investigated the effect of various dopamine receptor agonists and antagonists on the lipopolysaccharide-induced production of tumor necrosis factor-alpha and NO in mice. Pretreatment of animals with bromocryptine or quinpirole, agonists of D2 dopamine receptors caused a blunting of both the tumor necrosis factor-α and NO responses to lipopolysaccharide injected intraperitoneally. Sulpiride, an antagonist of dopamine D2 receptors, decreased the lipopolysaccharide-induced tumor necrosis factor-α plasma levels in a dose-dependent manner and inhibited the lipopolysaccharideinduced nitric oxide production by peritoneal macrophages. Bromocryptine or quinpirole, agonists of Da dopamine receptors, blunted both the tumor necrosis factor-a and NO response to lipopolysaccharide. SCH-23390, an antagonist of dopamine DI receptors did not alter lipopolysaccharide-induced tumor necrosis factor-a production, but inhibited lipopolysaccharide-induced NO production. These results indicate that while the D£ dopamine receptor is involved in the modulation of both lipopolysaccharide-induced tumor necrosis factor-α and NO production. DI dopamine receptors only regulate NO production. As many drugs possess effect on D2 dopamine receptors, our observations may be of clinical relevance.

Original languageEnglish
JournalFASEB Journal
Volume10
Issue number3
Publication statusPublished - 1996

Fingerprint

Dopamine Antagonists
Dopamine Agonists
lipopolysaccharides
agonists
tumor necrosis factor-alpha
nitric oxide
Lipopolysaccharides
antagonists
Nitric Oxide
Tumor Necrosis Factor-alpha
Modulation
tumor necrosis factors
mice
Dopamine Receptors
bromocriptine
Quinpirole
Bromocriptine
Dopamine D2 Receptors
dopamine
septic shock

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Modulation of lipopolysaccharide-induced tumor necrosis factor-alpha and nitric oxide production by dopamine receptor agonists and antagonists in mice. / Haskó, G.; Szabé, C.; Merkel, K.; Bencsics, A.; Zingarelli, B.; Vízi, E.

In: FASEB Journal, Vol. 10, No. 3, 1996.

Research output: Contribution to journalArticle

@article{b1e2a2275586420584f86cfdd8aef625,
title = "Modulation of lipopolysaccharide-induced tumor necrosis factor-alpha and nitric oxide production by dopamine receptor agonists and antagonists in mice",
abstract = "Dopamine and different dopaminergic drugs are widely used in the treatment of several immune-mediated diseases like Parkinson's disease or septic shock.Tumor necrosis factor-α and the free radical nitric oxide (NO) have been implicated in the pathogenesis of these pathophysiologic conditions. In the present study we have therefore investigated the effect of various dopamine receptor agonists and antagonists on the lipopolysaccharide-induced production of tumor necrosis factor-alpha and NO in mice. Pretreatment of animals with bromocryptine or quinpirole, agonists of D2 dopamine receptors caused a blunting of both the tumor necrosis factor-α and NO responses to lipopolysaccharide injected intraperitoneally. Sulpiride, an antagonist of dopamine D2 receptors, decreased the lipopolysaccharide-induced tumor necrosis factor-α plasma levels in a dose-dependent manner and inhibited the lipopolysaccharideinduced nitric oxide production by peritoneal macrophages. Bromocryptine or quinpirole, agonists of Da dopamine receptors, blunted both the tumor necrosis factor-a and NO response to lipopolysaccharide. SCH-23390, an antagonist of dopamine DI receptors did not alter lipopolysaccharide-induced tumor necrosis factor-a production, but inhibited lipopolysaccharide-induced NO production. These results indicate that while the D£ dopamine receptor is involved in the modulation of both lipopolysaccharide-induced tumor necrosis factor-α and NO production. DI dopamine receptors only regulate NO production. As many drugs possess effect on D2 dopamine receptors, our observations may be of clinical relevance.",
author = "G. Hask{\'o} and C. Szab{\'e} and K. Merkel and A. Bencsics and B. Zingarelli and E. V{\'i}zi",
year = "1996",
language = "English",
volume = "10",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "3",

}

TY - JOUR

T1 - Modulation of lipopolysaccharide-induced tumor necrosis factor-alpha and nitric oxide production by dopamine receptor agonists and antagonists in mice

AU - Haskó, G.

AU - Szabé, C.

AU - Merkel, K.

AU - Bencsics, A.

AU - Zingarelli, B.

AU - Vízi, E.

PY - 1996

Y1 - 1996

N2 - Dopamine and different dopaminergic drugs are widely used in the treatment of several immune-mediated diseases like Parkinson's disease or septic shock.Tumor necrosis factor-α and the free radical nitric oxide (NO) have been implicated in the pathogenesis of these pathophysiologic conditions. In the present study we have therefore investigated the effect of various dopamine receptor agonists and antagonists on the lipopolysaccharide-induced production of tumor necrosis factor-alpha and NO in mice. Pretreatment of animals with bromocryptine or quinpirole, agonists of D2 dopamine receptors caused a blunting of both the tumor necrosis factor-α and NO responses to lipopolysaccharide injected intraperitoneally. Sulpiride, an antagonist of dopamine D2 receptors, decreased the lipopolysaccharide-induced tumor necrosis factor-α plasma levels in a dose-dependent manner and inhibited the lipopolysaccharideinduced nitric oxide production by peritoneal macrophages. Bromocryptine or quinpirole, agonists of Da dopamine receptors, blunted both the tumor necrosis factor-a and NO response to lipopolysaccharide. SCH-23390, an antagonist of dopamine DI receptors did not alter lipopolysaccharide-induced tumor necrosis factor-a production, but inhibited lipopolysaccharide-induced NO production. These results indicate that while the D£ dopamine receptor is involved in the modulation of both lipopolysaccharide-induced tumor necrosis factor-α and NO production. DI dopamine receptors only regulate NO production. As many drugs possess effect on D2 dopamine receptors, our observations may be of clinical relevance.

AB - Dopamine and different dopaminergic drugs are widely used in the treatment of several immune-mediated diseases like Parkinson's disease or septic shock.Tumor necrosis factor-α and the free radical nitric oxide (NO) have been implicated in the pathogenesis of these pathophysiologic conditions. In the present study we have therefore investigated the effect of various dopamine receptor agonists and antagonists on the lipopolysaccharide-induced production of tumor necrosis factor-alpha and NO in mice. Pretreatment of animals with bromocryptine or quinpirole, agonists of D2 dopamine receptors caused a blunting of both the tumor necrosis factor-α and NO responses to lipopolysaccharide injected intraperitoneally. Sulpiride, an antagonist of dopamine D2 receptors, decreased the lipopolysaccharide-induced tumor necrosis factor-α plasma levels in a dose-dependent manner and inhibited the lipopolysaccharideinduced nitric oxide production by peritoneal macrophages. Bromocryptine or quinpirole, agonists of Da dopamine receptors, blunted both the tumor necrosis factor-a and NO response to lipopolysaccharide. SCH-23390, an antagonist of dopamine DI receptors did not alter lipopolysaccharide-induced tumor necrosis factor-a production, but inhibited lipopolysaccharide-induced NO production. These results indicate that while the D£ dopamine receptor is involved in the modulation of both lipopolysaccharide-induced tumor necrosis factor-α and NO production. DI dopamine receptors only regulate NO production. As many drugs possess effect on D2 dopamine receptors, our observations may be of clinical relevance.

UR - http://www.scopus.com/inward/record.url?scp=33749132581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749132581&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749132581

VL - 10

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 3

ER -